Literature DB >> 20944758

Clostridium difficile-associated diarrhea in a tertiary care medical center.

Marilee D Obritsch1, Jeffrey S Stroup, Ryan M Carnahan, David N Scheck.   

Abstract

This retrospective, case-control study aimed to identify variables associated with the incidence of Clostridium difficile-associated diarrhea (CDAD) in acute care facilities and to specifically identify the relationship of fluoroquinolones and acid suppressive agents in the development of CDAD. Seventy-one symptomatic patients positive for C. difficile toxin A or B hospitalized for at least 72 hours were compared with 142 control patients hospitalized for at least 72 hours who were not positive for C. difficile toxin A or B. Two controls were matched to one case patient for age within 5 years, unit of admission, and date of admission. The mean ages for cases and controls were 63.5 and 62.7 years, respectively. After adjusting for two confounding variables-hospital stay within 3 months and Charlson Comorbidity Index-conditional multiple logistic regression identified six risk factors for development of CDAD: gastrointestinal procedures within 60 days (odds ratio [OR] 9.1, P < 0.013), levofloxacin exposure (OR 8.2, P < 0.033), moxifloxacin exposure (OR 4.1, P < 0.026), imipenem exposure (OR 14.9, P < 0.014), laxative use (OR 20.2, P < 0.0001), and immunosuppressive use (OR 20.7, P < 0.034). The risk of CDAD after exposure to levofloxacin or moxifloxacin was not significantly different. Acid suppressive therapy was not a risk factor for CDAD development.

Entities:  

Year:  2010        PMID: 20944758      PMCID: PMC2943450          DOI: 10.1080/08998280.2010.11928654

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  44 in total

1.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

2.  Pseudomembranous colitis associated with ciprofloxacin.

Authors:  D B Cain; M E O'Connor
Journal:  Lancet       Date:  1990-10-13       Impact factor: 79.321

3.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

4.  Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea.

Authors:  C Yip; M Loeb; S Salama; L Moss; J Olde
Journal:  Infect Control Hosp Epidemiol       Date:  2001-09       Impact factor: 3.254

5.  A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.

Authors:  Sophia V Kazakova; Kim Ware; Brittany Baughman; Oleg Bilukha; Anne Paradis; Stephen Sears; Angie Thompson; Bette Jensen; Lois Wiggs; Jemelie Bessette; James Martin; Judy Clukey; Kathleen Gensheimer; George Killgore; L Clifford McDonald
Journal:  Arch Intern Med       Date:  2006 Dec 11-25

Review 6.  Clostridium difficile infection.

Authors:  D H Gröschel
Journal:  Crit Rev Clin Lab Sci       Date:  1996       Impact factor: 6.250

7.  Severe pseudomembranous colitis after moxifloxacin use: a case series.

Authors:  Jason C Gallagher; Jennifer K Du; Christina Rose
Journal:  Ann Pharmacother       Date:  2008-12-09       Impact factor: 3.154

8.  A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics.

Authors:  K W Garey; T K Dao-Tran; Z D Jiang; M P Price; L O Gentry; H L Dupont
Journal:  J Hosp Infect       Date:  2008-08-23       Impact factor: 3.926

9.  Moxifloxacin-induced Clostridium difficile-associated diarrhea.

Authors:  Douglas N Carroll
Journal:  Pharmacotherapy       Date:  2003-11       Impact factor: 4.705

10.  Waterlow score to predict patients at risk of developing Clostridium difficile-associated disease.

Authors:  J Tanner; D Khan; D Anthony; J Paton
Journal:  J Hosp Infect       Date:  2009-01-21       Impact factor: 3.926

View more
  3 in total

1.  Community-acquired Clostridium difficile infection in Serbian pediatric population.

Authors:  Stojanović Predrag; Kocić Branislava; Stojanović Nikola; Radulovic Niko; Stojanović-Radić Zorica; Dobrila Stanković-Đorđević
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-01       Impact factor: 3.267

2.  Analysis of risk factors and clinical manifestations associated with Clostridium difficile disease in Serbian hospitalized patients.

Authors:  Stojanović Predrag
Journal:  Braz J Microbiol       Date:  2016-07-25       Impact factor: 2.476

3.  An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides difficile Colonization and Hinders Clearance.

Authors:  Sarah Tomkovich; Ana Taylor; Jacob King; Joanna Colovas; Lucas Bishop; Kathryn McBride; Sonya Royzenblat; Nicholas A Lesniak; Ingrid L Bergin; Patrick D Schloss
Journal:  mSphere       Date:  2021-09-29       Impact factor: 4.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.